Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy

HAEMA

Volumn 7, Issue 3, 2004, Pages 329-334

  Catalano, Lucio ^a   Andretta, Claudia ^a   Pace, Leonardo ^a,b   Del Vecchio, Silvana ^b   Fonti, Rosa ^b   Pollio, Giuditta ^a   Salvatore, Barbara ^a   Esposito, Carmine ^c   Salvatore, Marco ^a,b   Rotoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c LEONARDO S P A   (Italy)

Author keywords

Myeloma; Scintigraphy; Solitary plasmacytoma; Tc99m sestaMIBI

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PLASMACYTOMA; PROGNOSIS; SCINTIGRAPHY; X RAY;

EID: 4043074828     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ciu ML, Kronauge JF, Piwnica-Worms D. Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis(2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblast. J Nucl Med 1990; 31: 1646-1653.
2. Del Vecchio S, Ciarmiello A, Salvatore M. Clinical imaging of multidrug resistance in cancer. Q J Nucl Med 1999; 43: 125-131.
3. Kostkiewicz M, Tracz W, Przewlocki T, Kawalec E. Predictive potential of noninvasive methods, inclusive of exercise SPECT Tc99m MIBI imaging, in recognition of high-risk patients with left main coronary artery stenosis. Int J Cardiovasc Imaging 2001; 17: 347-352.
4. Hassan I, Sahweil A, Costantinides C et al. Uptake and kinetics of tc-99m hexakis 2- methoxyisobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14: 333-340
5. Caner B, Kitapci M, Aras T et al. Increased accumulation of 2-methoxyisobutylisonitrile technetium in osteosarcoma and its metastatic lymph nodes. J Nucl Med 1991; 32: 1977-1978.
6. 99mTc-MIBI. Clin Nucl Med 1993; 18: 217-219.
7. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m-methoxyisobutyl isonitrile brest scintigraphy to evalue palpable brest masses. Eur J Nucl Med 1994; 21: 432-436.
8. Wakasugi S, Teshima H, Nakamura H et al. Tc-99m MIBI localization in bone marrow: a marker of bone marrow malignancy. Clin Nucl Med 1998; 23: 664-671.
9. Tirovola EB, Biassoni L, Britton KE, et al. The use of Tc-99m MIBI scanning in multiple myeloma. Br J Cancer 1996; 74: 1815-1820.
10. Adams BK, Fataar A, Nizami MA. Technetium-99m-sestaMIBI uptake in myeloma. J Nucl Med 1996; 37: 1001-1002.
11. Pace L, Catalano L, Del Vecchio S et al. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow up. Eur J Nucl Med 2001; 28: 304-312.
12. Balleari E, Villa G, Garre S et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001; 86: 78-84.
13. Svaldi M, Tappa C, Gebert U et al. Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Ann Hematol 2001; 80: 393-397.
14. Fonti R, Del Vecchio S, Zanetti A et al. Bone marrow uptake of 99m Tc-MIBI in patients with multiple myeloma. Eur J Nucl Med 2001; 28: 214-220.
15. Pace L, Catalano L, Pinto AM et al. Different patterns of technetium-99m-sestaMIBI in multiple myeloma. Eur J Nucl Med 1998; 25: 715-720.
16. Ciarmiello A, Del Vecchio S, Silvestro P et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
17. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cells tumors of bone. J Clin Oncol 1983; 1: 255-262.
18. Holland J, Trenkner DA, Wasserman TH, Finegerg B. Plasmacytoma. Cancer 1991; 69: 1513-1517.
19. Mayr NA, Wen BC, Hussey DH et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 1990; 17: 293-303.
20. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology 2000; 14: 101-108
21. Liebross Rh, Ha CS, Cox JD et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 1999; 52: 245-249
22. Wilder RB, Ha CS, Cox JD, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002; 94: 1532-1537
23. Galieni P, Cavo M, Avvisati G et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol 1995; 6: 687-691.
24. Galieni P, Cavo M, Pulsoni A et al. Clinical outcome of extramedullary plasmacytoma. Haematologica 2000; 85: 47-51.
25. Dimopoulos MA, Moulopoulos A, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000; 96: 2037-2044.
26. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002; 31: 690-694.
27. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high risk myeloma. J Nucl Med 2002; 43: 1457-1463.
28. 8F-FDG PET, Eur J Nucl Med 2002; 29: 361-366.
29. Catalano L, Pace L, Califano C et al. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica 1999; 84: 119-124.
30. Masini L, Prosperi D, Gamberi B et al. Role of conventional skeletal X ray, Tc99-MDP scintigraphy and Tc99m-sestamibi in the detection of bone lesions in multiple myeloma. (abstract). Haematologica 2002; (suppl. 87): 112.